×

FDA grants accelerated approval to GSK’s lung cancer drug

By Thomson Reuters Nov 17, 2026 | 11:38 AM

Nov 17 (Reuters) – The ​US ‌FDA on Tuesday ‌granted ​accelerated ⁠approval ⁠to GSK’s drug for ​patients ⁠with ⁠an ​advanced form ​of lung ‌cancer, whose ⁠disease has progressed after ⁠earlier ‌treatments.

(Reporting ⁠by ​Kamal ‌Choudhury ​in Bengaluru; ⁠Editing by Shailesh ​Kuber)